Monoclonal antibodies have been an effective tool in the battle against COVID-19, reducing the risk of hospitalization or death by 39% for people who started the treatment within two days of a positive test, a new study finds. These treatments were even more effective for immunocompromised people, regardless of age, according to the University of Pittsburgh researchers. “The virus was a moving target, and, for two years, monoclonal antibodies were approved, revoked, sometimes reauthorized and sometimes scarce,” said Kevin Kip, lead author of a new analysis and vice president of clinical analytics at University of Pittsburgh Medical Center (UPMC). “Using UPMC’s database of patients treated with monoclonal antibodies — one of the largest in the U.S. — we are finally able to conclude that pushing through all these challenges unequivocally saved lives and prevented hospitalizations,” Kip said in a university news release. The U.S. Food and Drug Administration granted emergency use authorization to five monoclonal antibodies between 2020 and 2022. These human-made antibodies were designed to prevent the virus from entering human cells where they could replicate and cause serious illness. Those used for COVID-19 were administered intravenously or through an injection. They were restricted to people aged 12 and older with risk factors that made them more susceptible to bad outcomes from the virus. As the virus evolved, so did the antibodies, with new… read on > read on >

















